Investing.com -- Wellgistics Health Inc (NASDAQ:WGRX) stock surged 9.2% on Monday after the health information technology company announced the commercial launch of diabetes prescription drug ...
Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...
Wellgistics Health (WGRX) has begun the commercial launch of diabetes prescription drug Brenzavvy to its network of 6,500 independent pharmacies ...
MiBolsilloColombia on MSN
New 2026 price negotiations: What the first cuts on high-cost drugs mean for pharmacies
Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...
The new rule is expected to extend the telemedicine flexibilities through the end of 2026 and will maintain the status quo while the DEA and the Department of Health and Human Services work toward a ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...
CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...
Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found.
Question: I paid so much for my Eliquis this year, will I have to pay that much next year too? Answer: The good news is no, seniors will not pay as much for Eliquis as well as nine other common ...
Currently, I am on a stand-alone Part D plan with a Medicare supplement because of my serious health issues. Last week, I received information about the changes to the 2026 Medicare Part D plan I am ...
Ipca Laboratories was named in a patent infringement lawsuit on Sept. 29 in Delaware District Court over its plans to market generic versions of the diabetes medication Jardiance. The action, brought ...
Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results